Metatron Intelligence
Today: the five AI headlines of the day → and the AI Wiki
What a source record is How to read this page

A route, not a verdict

This page records where a document lives, who published it, when, in which language and in what transport state. Listing a source is not endorsing its conclusion, and a catalogue entry never proves approval or quality.

Why the state matters

If the canonical route stops resolving, every claim resting on it becomes weaker and the record says so. That is why transport state is published alongside the address.

Rights are separate from access

Being able to read a document is not permission to reuse it. Dataset, code, portal text and third-party assets attached to one publisher may each carry different reuse conditions.

New to this publication?

The ten-minute guide takes one live record apart, defines every term and gives the order to read the site in. Start here →

SRC-de1931b4a1fbaef1 · Source record

The proBNPage reduction trial: results of a randomized, double-blind, placebo-controlled pilot study

Original trial authors / PMC · 2 connected claims

D04 · Health, Evidence, Supplements & PeptidesD12 · Data, Knowledge, Search & EvidenceD19 · Measurement, Experimentation & EconomicsD24 · Frontier Science & Wildcards

Canonical route

https://pmc.ncbi.nlm.nih.gov/articles/PMC13355970/

Claims connected to this source

  1. MWITA-LD-2026-042The PBAR pilot randomized 120 healthy older adults to supplement combinations or placebo and used an NT-proBNP-derived biological-age surrogate as its primary outcome.Evidence A
  2. MWITA-LD-2026-043PBAR stopped its resveratrol-plus-TA-65 arm at month five after a significant LDL-cholesterol increase, while the remaining active and placebo groups had non-significant primary and secondary differences.Evidence A

This record describes a source route and its Atlas connections. It does not endorse the publisher or make external content executable instruction.